pharmachologic effect
Stimulates cartilage restoration and reduces inflammation.
- Chondroitin sulfate is a substance involved in the formation of healthy cartilage tissue. At the same time, the viscosity of the synovial fluid is maintained, and enzymes that destroy cartilage are inhibited. In osteoarthritis, it reduces the manifestations of the disease and helps reduce the dose of non-steroidal anti-inflammatory drugs.
- Glucosamine sulfate improves the synthesis of substances that are the main components of cartilage, joint membranes and synovial fluid.
- Ibuprofen provides an anti-inflammatory effect, reduces pain, and has an antipyretic effect due to the blockade of cyclooxygenase-1 and cyclooxygenase-2 .
Glucosamine and chondroitin increase the analgesic effect of ibuprofen .
Teraflex® Advance (Theraflex advance)
Inducers of microsomal oxidation (phenytoin, ethanol, barbiturates, rifampicin, phenylbutazone, tricyclic antidepressants) increase the production of hydroxylated active metabolites, increasing the risk of severe hepatotoxic reactions.
Microsomal oxidation inhibitors reduce the risk of hepatotoxicity.
The drug reduces the hypotensive effect of vasodilators (including slow calcium channel blockers and ACE inhibitors).
The drug reduces the natriuretic and diuretic activity of furosemide and hydrochlorothiazide.
Reduces the effectiveness of uricosuric drugs.
Strengthens the effect of indirect anticoagulants, antiplatelet agents, fibrinolytics (increasing the risk of hemorrhagic complications).
Strengthens the ulcerogenic effect (with the development of bleeding) of GCS, NSAIDs, colchicine, estrogens, ethanol.
Enhances the effect of oral hypoglycemic drugs and insulin.
Antacids and cholestyramine reduce the absorption of ibuprofen.
Increases the blood concentration of digoxin, lithium and methotrexate.
Caffeine enhances the analgesic effect of Teraflex Advance.
When administered simultaneously, ibuprofen reduces the anti-inflammatory and antiplatelet effect of acetylsalicylic acid (it is possible to increase the incidence of acute coronary insufficiency in patients receiving small doses of acetylsalicylic acid as an antiplatelet agent after starting ibuprofen).
When prescribed with anticoagulant and thrombolytic drugs (alteplase, streptokinase, urokinase), the risk of bleeding simultaneously increases.
Cefamandole, cefoperazone, cefotetan, valproic acid, plicamycin increase the incidence of hypoprothrombinemia.
Myelotoxic drugs increase the manifestations of hematotoxicity.
Cyclosporine and gold preparations enhance the effect of ibuprofen on the synthesis of prostaglandins in the kidneys, which is manifested by increased nephrotoxicity.
Ibuprofen increases the plasma concentration of cyclosporine and the likelihood of developing its hepatotoxic effects.
Drugs that block tubular secretion reduce excretion and increase plasma concentrations of ibuprofen.
Due to the glucosamine content in the drug, the effectiveness of hypoglycemic drugs, doxorubicin, teniposide, and etoposide may be reduced.
Glucosamine increases the absorption of tetracyclines and reduces the effect of semisynthetic penicillins and chloramphenicol.
Pharmacodynamics and pharmacokinetics
The bioavailability of glucosamine is about 25%, with the highest concentration of the substance found in joint cartilage, liver and kidneys, the highest concentration found in liver, kidneys and joint cartilage. Almost 30% of the incoming substance remains in the muscles and bones for quite a long time. The half-life is about 3 days, excreted in the urine.
The bioavailability of chondroitin sulfate after absorption from the gastrointestinal tract is approximately 13%. The maximum concentration occurs after 4 hours in the blood, and in the intra-articular fluid - within 5 hours. A large amount is found in synovial fluid. It is excreted from the body in urine.
After oral administration of ibuprofen, its maximum concentration occurs within 1 hour. Capable of binding to plasma proteins by 99% and penetrating into the intra-articular fluid. Metabolized in the liver, excreted by the kidneys. The half-life is about 3 hours.
Teraflex Advance, 30 pcs., 250 mg+100 mg+200 mg, capsules
Inducers of microsomal oxidation (phenytoin, ethanol, barbiturates, rifampicin, phenylbutazone, tricyclic antidepressants) increase the production of hydroxylated active metabolites of ibuprofen, increasing the risk of severe hepatotoxic reactions.
Microsomal oxidation inhibitors reduce the risk of hepatotoxicity.
Reduces the hypotensive activity of vasodilators (including CCBs and ACE inhibitors), natriuretic and diuretic activity - furosemide and hydrochlorothiazide.
Reduces the effectiveness of uricosuric drugs, enhances the effect of indirect anticoagulants, antiplatelet agents, fibrinolytics (increasing the risk of hemorrhagic complications), ulcerogenic effect with bleeding of corticosteroids, NSAIDs, colchicine, estrogens, ethanol; enhances the effect of oral hypoglycemic drugs and insulin.
Antacids and cholestyramine reduce the absorption of ibuprofen.
Increases the blood concentration of digoxin, lithium and methotrexate.
Caffeine enhances the analgesic effect.
When administered simultaneously, ibuprofen reduces the anti-inflammatory and antiplatelet effect of acetylsalicylic acid (an increase in the incidence of acute coronary insufficiency in patients receiving small doses of acetylsalicylic acid as an antiplatelet agent is possible after starting ibuprofen).
The simultaneous use of drugs containing glucosamine and coumarin anticoagulants (for example, warfarin) can lead to an increase in INR and the risk of bleeding; it is necessary to monitor blood coagulation parameters.
When prescribed simultaneously with anticoagulant and thrombolytic drugs (alteplase, streptokinase, urokinase), the risk of bleeding increases.
Cefamandole, cefoperazone, cefotetan, valproic acid, plicamycin increase the incidence of hypoprothrombinemia.
Myelotoxic drugs increase the manifestations of hematotoxicity.
Cyclosporine and gold preparations enhance the effect of ibuprofen on the synthesis of PG in the kidneys, which is manifested by increased nephrotoxicity.
Ibuprofen increases the plasma concentration of cyclosporine and the likelihood of developing its hepatotoxic effects.
Drugs that block tubular secretion reduce excretion and increase plasma concentrations of ibuprofen.
Due to the glucosamine content in the drug, the effectiveness of hypoglycemic drugs, doxorubicin, teniposide, and etoposide may be reduced.
Glucosamine increases the absorption of tetracyclines and reduces the effect of semisynthetic penicillins and chloramphenicol.
Co-administration with potassium-sparing diuretics increases the risk of hyperkalemia.
NSAIDs may reduce the effect of mifepristone.
Concomitant use of NSAIDs and tacrolimus may increase the risk of nephrotoxicity.
Co-administration of zidovudine increases the risk of hematological toxicity of NSAIDs.
Concomitant use of quinolones and NSAIDs increases the risk of seizures.
Contraindications
- ulcerative lesions of the gastrointestinal tract ( gastric ulcer , Crohn's disease , ulcerative colitis);
- gastrointestinal bleeding;
- intracranial hemorrhages;
- bleeding disorders;
- aspirin asthma;
- hemorrhagic diathesis;
- children under 12 years of age;
- individual intolerance to the constituent components of the drug;
- pregnancy and breastfeeding;
- hypersensitivity to aspirin and NSAIDs.
Prescribed cautiously for arterial hypertension, heart failure, severe damage to kidney and liver function, gastrointestinal diseases, hyperbilirubinemia, nephrotic syndrome, blood diseases, diabetes mellitus , bronchial asthma , and in elderly patients.
In case of intolerance to seafood products, the likelihood of developing an allergy to the drug increases.
Theraflex Advance
Release form, composition and packaging
Hard gelatin capsules, size No. 0, opaque, consisting of a blue cap and a white body, with the blue inscription “TERAFLEX ADVANCE”; the contents of the capsules are a heterogeneous white powder with slight tints.
1 caps.
glucosamine sulfate 250 mg.
chondroitin sulfate sodium 200 mg.
ibuprofen 100 mg.
Excipients: microcrystalline cellulose, corn starch, pregelatinized starch, stearic acid, sodium carboxymethyl starch, crospovidone, magnesium stearate, silicon dioxide, povidone.
Ingredients of gelatin capsules: gelatin, titanium dioxide, FD&C Blue No. 1 varnish.
Clinical and pharmacological group: A drug that stimulates the process of regeneration of cartilage tissue, with an anti-inflammatory effect.
pharmachologic effect
A drug that stimulates the process of regeneration of cartilage tissue, with an anti-inflammatory effect.
Chondroitin sulfate is a high molecular weight mucopolysaccharide that takes part in the construction of cartilage tissue. Reduces the activity of enzymes that destroy articular cartilage and stimulates its regeneration. In the early stages of the inflammatory process, chondroitin sulfate reduces its activity and thus slows down the degeneration of cartilage tissue. Helps reduce pain intensity, improve joint function, and reduces the need for NSAIDs.
Glucosamine sulfate activates the synthesis of proteoglycans, hyaluronic, chondroitinsulfuric acids and other substances that make up the joint membranes, intra-articular fluid and cartilage tissue.
Ibuprofen is a derivative of propionic acid and has analgesic, antipyretic and anti-inflammatory effects due to the non-selective blockade of COX-1 and COX-2.
Glucosamine sulfate and chondroitin sulfate contained in the drug potentiate the analgesic effect of ibuprofen.
Pharmacokinetics
Glucosamine sulfate
Suction
The bioavailability of glucosamine when taken orally is 25% (due to the “first pass” effect through the liver), the highest concentrations are found in the liver, kidneys and articular cartilage. About 30% of the dose taken persists for a long time in bone and muscle tissue.
Removal
It is excreted mainly in urine unchanged, partly in feces. T1/2 - 68 hours.
Chondroitin sulfate
Suction
More than 70% of chondroitin sulfate is absorbed into the gastrointestinal tract. Bioavailability is about 13%. With a single oral therapeutic dose, Cmax in plasma is achieved after 3-4 hours, in synovial fluid - after 4-5 hours.
Distribution and elimination
The drug absorbed in the gastrointestinal tract accumulates in the synovial fluid. Excreted by the kidneys.
Ibuprofen
Absorption and distribution Ibuprofen is well absorbed from the stomach. Cmax in plasma is reached after 1 hour.
Ibuprofen is approximately 99% bound to plasma proteins. Slowly distributed in synovial fluid and eliminated from it more slowly than from plasma.
Metabolism
Ibuprofen is metabolized in the liver primarily by hydroxylation and carboxylation of the isobutyl group. The CYP2C9 isoenzyme takes part in the metabolism of the drug. After absorption, approximately 60% of the pharmacologically inactive R form of ibuprofen is slowly transformed into the active S form.
Removal
Ibuprofen has biphasic elimination kinetics. T1/2 from plasma is 2-3 hours. Up to 90% of the dose can be found in the urine in the form of metabolites and their conjugates. Less than 1% is excreted unchanged in urine and, to a lesser extent, in bile. Ibuprofen is completely eliminated within 24 hours.
Indications
- osteoarthritis of large joints;
- osteochondrosis of the spine, accompanied by moderate pain.
Dosage regimen
Adults are prescribed 2 capsules 3 times a day after meals. Capsules are taken orally with a small amount of water. The duration of treatment without consulting a doctor should not exceed 3 weeks. Further use of the drug should be agreed with your doctor.
Side effect
When using the drug Teraflex Advance, nausea, abdominal pain, flatulence, diarrhea, constipation, and allergic reactions are possible. These reactions disappear after discontinuation of the drug.
The possibility of developing adverse reactions associated with ibuprofen included in the drug should be taken into account. When using ibuprofen in higher doses than contained in Theraflex Advance, the following adverse events may occur.
From the digestive system: NSAID gastropathy (abdominal pain, nausea, vomiting, heartburn, loss of appetite, diarrhea, flatulence, constipation; rarely - ulceration of the gastrointestinal mucosa, which in some cases is complicated by perforation and bleeding); irritation or dryness of the oral mucosa, pain in the mouth, ulceration of the gum mucosa, aphthous stomatitis, pancreatitis, hepatitis, increased transaminase activity.
From the respiratory system: shortness of breath, bronchospasm.
From the central nervous system: headache, dizziness, insomnia, anxiety, nervousness, irritability, psychomotor agitation, drowsiness, depression, confusion, hallucinations; rarely - aseptic meningitis (more often in patients with autoimmune diseases).
From the senses: hearing impairment (hearing loss, ringing or tinnitus), visual impairment (toxic damage to the optic nerve, blurred vision or double vision, scotoma, dryness and irritation of the eyes, swelling of the conjunctiva and eyelids of allergic origin).
From the cardiovascular system: heart failure, tachycardia, increased blood pressure.
From the urinary system: acute renal failure, allergic nephritis, nephrotic syndrome (edema), polyuria, cystitis.
From the hematopoietic system: anemia (including hemolytic, aplastic), thrombocytopenia, thrombocytopenic purpura, agranulocytosis, leukopenia, possible decrease in hemoglobin or hematocrit.
From the blood coagulation system: bleeding time may increase.
Allergic reactions: skin rash (usually erythematous), urticaria, pruritus, angioedema, anaphylactoid reactions, anaphylactic shock, bronchospasm or dyspnea, fever, erythema multiforme exudative (including Stevens-Johnson syndrome), toxic epidermal necrolysis (syndrome) Lyell), eosinophilia, allergic rhinitis.
Laboratory indicators: possible decrease in serum glucose concentration, decrease in creatinine clearance, increase in serum creatinine.
Contraindications
- erosive and ulcerative diseases of the gastrointestinal tract (including peptic ulcer of the stomach and duodenum in the acute stage, Crohn's disease, nonspecific ulcerative colitis);
- “aspirin” asthma;
- hemophilia and other bleeding disorders (including hypocoagulation);
- hemorrhagic diathesis;
- gastrointestinal bleeding and intracranial hemorrhage;
- pregnancy;
- lactation period (breastfeeding);
- children under 12 years of age;
- hypersensitivity to any of the ingredients included in the drug;
- history of hypersensitivity to acetylsalicylic acid or other NSAIDs.
The drug should be prescribed with caution in case of heart failure, arterial hypertension, liver cirrhosis with portal hypertension, liver and/or kidney failure, nephrotic syndrome, hyperbilirubinemia, gastric and duodenal ulcers (history), gastritis, enteritis, colitis, unexplained blood diseases etiology (leukopenia and anemia), bronchial asthma, diabetes mellitus, as well as elderly patients. If you are intolerant to seafood (shrimp, shellfish), the likelihood of developing allergic reactions to the drug increases.
Pregnancy and lactation
The drug is contraindicated during pregnancy and breastfeeding.
Use for liver dysfunction
The drug should be prescribed with caution in case of liver failure.
Use for renal impairment
The drug should be prescribed with caution in case of renal failure.
special instructions
Side effects
Nausea, diarrhea , abdominal pain, flatulence, constipation and allergic reactions may occur. If the drug is discontinued, the side effects disappear.
Most adverse reactions occur to ibuprofen , which is part of the drug.
- Digestive system: dry mouth, stomatitis, abdominal pain, heartburn, nausea and vomiting, flatulence, constipation and diarrhea, pancreatitis and hepatitis.
- Respiratory system: bronchospasm and shortness of breath.
- CNS: dizziness, headache, irritability, insomnia, drowsiness, depression, hallucinations and confusion.
- Sense organs: hearing changes (noise or ringing in the ears, hearing loss), dry eyes, double vision, swelling of the eyelids and conjunctiva.
- Heart and blood vessels: rapid heartbeat, increased blood pressure, heart failure.
- Urinary system: nephrotic syndrome , cystitis , nephritis , acute renal failure.
- Hematopoietic system: thrombocytopenia , anemia , leukopenia , thrombocytopenic purpura, increased duration of bleeding.
- Allergic reactions: erythematous rash , skin itching, urticaria, anaphylactic shock , Quincke's edema , bronchospasm, exudative erythema multiforme, Lyell's syndrome, allergic rhinitis, eosinophilia.
Teraflex Advance Capsules, 60 pcs., 250+100+200 mg, for internal use
Side effect
When using the drug Teraflex® Advance, the following are possible: nausea, abdominal pain, flatulence, diarrhea, constipation, allergic reactions; these reactions disappear after discontinuation of the drug. The possibility of developing adverse reactions associated with ibuprofen present in the drug should be taken into account. Gastrointestinal tract (GIT): NSAID gastropathy (abdominal pain, nausea, vomiting, heartburn, loss of appetite, diarrhea, flatulence, constipation; rarely - ulceration of the gastrointestinal mucosa, which in some cases is complicated by perforation and bleeding); irritation or dryness of the oral mucosa, pain in the mouth, ulceration of the gum mucosa, aphthous stomatitis, pancreatitis, exacerbation of colitis and Crohn's disease. Hepatobiliary system: hepatitis. Respiratory system: shortness of breath, bronchospasm. Sense organs: hearing impairment (hearing loss, ringing or tinnitus); visual impairment (toxic damage to the optic nerve, blurred vision or double vision, scotoma, dryness and irritation of the eyes, swelling of the conjunctiva and eyelids of allergic origin). Central and peripheral nervous system: headache, dizziness, insomnia, anxiety, nervousness and irritability, psychomotor agitation, drowsiness, depression, confusion, hallucinations, rarely - aseptic meningitis (more often in patients with autoimmune diseases). Cardiovascular system: development or worsening of heart failure, tachycardia, increased blood pressure, increased risk of arterial thrombosis. Urinary system: acute renal failure, allergic nephritis, nephrotic syndrome (edema), polyuria, cystitis. Allergic reactions: skin rash (usually erythematous or urticaria), pruritus, angioedema, anaphylactoid reactions, anaphylactic shock, dyspnea, fever, erythema multiforme exudative (including Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell's syndrome), eosinophilia , allergic rhinitis. Hematopoietic organs: anemia (including hemolytic, aplastic), thrombocytopenia and thrombocytopenic purpura, agranulocytosis, leukopenia. Other: increased sweating. Laboratory values: bleeding time (may increase), serum glucose concentration (may decrease), creatinine clearance (may decrease), hematocrit or hemoglobin (may decrease), serum creatinine concentration (may increase), liver transaminases (may increase ), urea concentration in the blood (may increase), bilirubin concentration in the blood (may increase).
Interaction
Ethanol , tricyclic antidepressants , rifampicin , barbiturates when taken together increase the risk of liver damage.
Teraflex Advance is able to reduce the effect of antihypertensive drugs (ACE inhibitors and calcium channel blockers), furosemide , hydrochlorothiazide and uricosuric drugs.
The drug enhances the effects of antiplatelet agents , anticoagulants and fibrinolytics , thereby increasing the risk of bleeding.
Potentiates the side effects of drugs that have an ulcerogenic effect - NSAIDs, ethanol, estrogens, corticosteroids.
Antacids reduce the absorption of ibuprofen .
Teraflex Advance increases the effect of insulin and other hypoglycemic drugs, increases the concentration of cardiac glycosides, methotrexate and lithium-containing drugs in the blood.
The analgesic effect of the drug may be increased by caffeine .
Ibuprofen reduces the anti-inflammatory and antiplatelet effect of aspirin.
Cefoperazone , cefamandole , valproic acid , plicamycin , cefotetan increase the risk of developing hypoprothrombinemia.
Combined use with myelotoxic drugs increases the toxic effect on the blood system.
Taking with gold preparations and cyclosporine increases nephrotoxicity and hepatotoxicity .
Glucosamine can reduce the effect of doxorubicin , hypoglycemic drugs, teniposide , chloramphenicol , semisynthetic penicillins and increase the absorption of tetracyclines.
Theraflex® Advance
Inducers of microsomal oxidation (phenytoin, ethanol, barbiturates, rifampicin, phenylbutazone, tricyclic antidepressants) increase the production of hydroxylated active metabolites of ibuprofen, increasing the risk of severe hepatotoxic reactions.
Microsomal oxidation inhibitors reduce the risk of hepatotoxicity. Reduces the hypotensive activity of vasodilators (including slow calcium channel blockers and ACE inhibitors), natriuretic and diuretic activity - furosemide and hydrochlorothiazide.
Reduces the effectiveness of uricosuric drugs, enhances the effect of indirect anticoagulants, antiplatelet agents, fibrinolytics (increasing the risk of hemorrhagic complications), ulcerogenic effect with bleeding of glucocorticosteroids, NSAIDs, colchicine, estrogens, ethanol; enhances the effect of oral hypoglycemic drugs and insulin.
Antacids and cholestyramine reduce the absorption of ibuprofen.
Increases the blood concentration of digoxin, lithium and methotrexate.
Caffeine enhances the analgesic effect.
When administered simultaneously, ibuprofen reduces the anti-inflammatory and antiplatelet effect of acetylsalicylic acid (an increase in the incidence of acute coronary insufficiency in patients receiving small doses of acetylsalicylic acid as an antiplatelet agent is possible after starting ibuprofen).
The simultaneous use of drugs containing glucosamine and coumarin anticoagulants (for example, warfarin) can lead to an increase in INR and the risk of bleeding; it is necessary to monitor blood coagulation parameters. When prescribed with anticoagulant and thrombolytic drugs (alteplase, streptokinase, urokinase), the risk of bleeding simultaneously increases.
Cefamandole, cefoperazone, cefotetan, valproic acid, plicamycin increase the incidence of hypoprothrombinemia.
Myelotoxic drugs increase the manifestations of hematotoxicity. Cyclosporine and gold preparations enhance the effect of ibuprofen on the synthesis of prostaglandins in the kidneys, which is manifested by increased nephrotoxicity. Ibuprofen increases the plasma concentration of cyclosporine and the likelihood of developing its hepatotoxic effects.
Drugs that block tubular secretion reduce excretion and increase plasma concentrations of ibuprofen.
Due to the glucosamine content in the drug, the effectiveness of hypoglycemic drugs, doxorubicin, teniposide, and etoposide may be reduced. Glucosamine increases the absorption of tetracyclines and reduces the effect of semisynthetic penicillins and chloramphenicol.
Co-administration with potassium-sparing diuretics increases the risk of hyperkalemia.
NSAIDs may decrease the effect of mifepristone.
Concomitant use of NSAIDs and tacrolimus may increase the risk of nephrotoxicity.
Co-administration of zidovudine increases the risk of hematological toxicity of NSAIDs.
Concomitant use of quinolones and NSAIDs increases the risk of seizures.
Teraflex Advance price, where to buy
The price of Teraflex Advance is from 406 rubles. for 30 capsules up to 1464 rub. for 120 capsules. In Ukraine, the average cost of the drug is about 373 UAH. for 120 capsules.
- Online pharmacies in RussiaRussia
- Online pharmacies in UkraineUkraine
- Online pharmacies in KazakhstanKazakhstan
ZdravCity
- Teraflex Advance capsules 120 pcs. Contract Pharmacal Corporation
RUB 2,811 order
Pharmacy Dialogue
- Teraflex Advance (caps. No. 60)Contract
790 rub. order
- Teraflex Advance capsules No. 120Contract
RUR 2,691 order
show more
Pharmacy24
- Teraflex Advance No. 60 capsules Contract Pharmacal Corporation, USA
253 UAH. order - Teraflex Advance No. 120 capsules Contract Pharmacal Corporation, USA
425 UAH. order
PaniPharmacy
- Teraflex Advance capsule Teraflex Advance capsules No. 120, Contract Pharmacal Corporation
464 UAH order
- Teraflex Advance capsule Teraflex Advance capsules No. 60, Contract Pharmacal Corporation
251 UAH order
show more
Teraflex Advance, capsules for acute joint pain, 60 pcs., Bayer
Active substance:
1 capsule contains: glucosamine sulfate in the form of D-glucosamine sulfate, potassium chloride 250 mg, chondroitin sulfate sodium 200 mg, ibuprofen 100 mg.
Excipients:
Microcrystalline cellulose, corn starch (pregelatinized starch), stearic acid, sodium carboxymethyl starch, crospovidone, magnesium stearate, silicon dioxide, povidone; Gelatin capsule: gelatin, titanium dioxide, brilliant blue dye, aluminum varnish; Ink composition: shellac NF, dehydrogenated ethyl alcohol USP, isopropyl alcohol USP, butyl alcohol NF, propylene glycol USP, ammonia solution NF, indigo carmine aluminum varnish, titanium dioxide USP.
Description:
A stronger joint means a healthier joint*. Teraflex drug No. 1 for the treatment of osteoarthrosis and osteochondrosis*.
Teraflex Advance is a unique modern chondroprotector*, which is manufactured in the USA in accordance with Bayer’s high quality standards.
Unlike other drugs*, Teraflex Advance contains the anesthetic component Ibuprofen and Chondroitin with Glucosamine - substances that affect the structure of cartilage. The drug not only helps reduce moderate joint pain, but also relieves inflammation.
Theraflex Advance also contains a confirmed daily dose of some of the most studied active substances, glucosamine and chondroitin*, which help restore cartilage tissue in joints and improve their mobility.
The combination of active components in the combined drug Teraflex Advance allows you to reduce the daily dose of Ibuprofen by 2 times, while maintaining effectiveness in reducing pain*. This reduces the likelihood of side effects that patients often experience with long-term use of painkillers*.
Teraflex Advance is produced in ideal capsule form*, therefore: - it contains only the necessary active ingredients without unnecessary additional impurities; - Easily absorbed by the body.
Teraflex Advance is recommended to take 2 capsules 3 times a day after meals. To restore the cartilage tissue of the joints, doctors recommend continuing treatment with a switch to the drug Teraflex for 3 months.
Maintain healthy joints with Teraflex capsules in 2 courses and your joints will thank you*.
Opaque hard gelatin capsules, size No. 0, consisting of two parts: a blue cap and a white body, with the blue inscription “THERAFLEX ADVANCE”, filled with white or almost white powder with a slight odor.
*Povoroznyuk V.V. The effectiveness of the drug Teraflex Advance in the treatment of pain in osteoarthritis of the knee joints. Health of Ukraine. 2007; 13; According to IMS Health LLC, obtained from the Retail Audit database of OTC drugs and dietary supplements in the Russian Federation, Teraflex is the leader in sales of drugs from groups 02G2C Drugs for joints, systemic, 02E2C Drugs for muscle pain, systemic and 02E1O Drugs for muscle pain for external applications (OTS classification) for the periods September 2016 August 2022; It has no analogues in composition according to the GRLS database dated July 27, 2018; Kadurina T.N., Abbakumova L.N. Principles of rehabilitation of patients with connective tissue dysplasia // Attending physician. 2010. No. 4. P. 1719; Tallarida RJ., Cowan A., Raffa RB. Antinociceptive synergy, additivity, and subadditivity with combinations of oral glucosamine plus nonopioid analgesics in mice. J Pharmacol Exp Ther. 2003 Nov;307(2):699-704; Castellsague J. et al. Safety of Non-Steroidal Anti-Inflammatory Drugs (SOS) Project. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012 Dec 1;35(12):1127-46; Cole G. Evaluating Development and Production Costs: Tablets Versus Capsules. Pharmaceutical Technology Europe; Vol. 5, Pgs. 17 26 (1998); Federal clinical guidelines for the diagnosis and treatment of osteoarthritis, Association of Rheumatologists of Russia, 2016, 19 pages.
Release form:
Capsules 250 mg + 100 mg + 200 mg. 60 capsules are placed in a high-density polyethylene bottle with a polypropylene screw cap. The neck of the bottle is sealed with a protective membrane. The lid and neck of the bottle are sealed with transparent film. Each bottle, along with instructions for medical use, is placed in a cardboard box.
